FDA's Clinical Hold Doesn't Affect Magenta Therapeutics' (MGTA) MGTA-117 Prospects - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Magenta Therapeutics (MGTA) PT Lowered to $20 at Wedbush, Following Clinical Business Update
July 21, 2021 9:59 AM EDTWedbush analyst David Nierengarten lowered the price target on Magenta Therapeutics (NASDAQ: MGTA) to $20.00 (from $22.00) while maintaining a Outperform rating.
... MorePre-Open Stock Movers 07/21: (CEMI) (LE) (SDC) Higher; (SNBR) (FOUR) (MGTA) Lower (more...)
July 21, 2021 9:20 AM EDTPre-Open Stock Movers
Chembio Diagnostics, Inc. (Nasdaq: CEMI) 92.7% HIGHER; announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembios DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazils Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a... More
Magenta Therapeutics (MGTA) to Resume Trading at 8:30 a.m.
July 21, 2021 8:08 AM EDTMagenta Therapeutics (NASDAQ: MGTA) to Resume Trading at 8:30 a.m.
... MoreMagenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS
July 21, 2021 8:01 AM EDTMagenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The FDA is requiring that Magenta develop an additional bioassay to be used in conjunction with the PK/PD model to inform dose escalation decisions in addition to safety monitoring. This was the only clinical... More
Magenta Therapeutics (MGTA) Halted, News Pending
July 21, 2021 7:55 AM EDTMagenta Therapeutics (NASDAQ: MGTA) Halted, News Pending
... More